In 2019, Curtis Hodge and Greg Hura established Nanotein building off of a technology they developed at Lawrence Berkeley National Lab. To achieve this they combined their expertise in protein structure, function, and engineering with their understanding of cellular biology and cancer immunology.
Nanotein partnered with Polaris Group, a developer of novel cancer treatments, in 2020. Polaris is a major investor and manufacturing partner of Nanotein.
Nanotein is interested in collaborations.
A structural biologist, protein biochemist, and immunologist by training, Curtis invented Nanotein’s core platform technology and acts as Nanotein’s CEO, driving the company’s day-to-day operations.
Prior to Nanotein, Curtis was a postdoc in Greg’s lab at LBNL. It’s here where the earliest iterations of Nanotein’s technology were born; work that ultimately culminated in the formation of Nanotein as a company and subsequent selection as a Top Emerging Biotech by UC Berkeley and UCSF’s QB3.
A proud native of Alberta, Canada Curtis earned his PhD in Biochemistry from the University of Alberta. From here he moved to California for a postdoc in cancer immunology at UC Berkeley, then to LBNL and the rest is history.
Greg Hura is a Principal Investigator & Beamline Research Scientist at Lawrence Berkeley National Lab and an Associate Adjunct Professor at the University of California, Santa Cruz. Greg has a PhD in Biophysics from UC Berkeley and was a pioneering developer of high-throughput small-angle X-ray Scattering (SAXS) internationally. He also created SAXS tools of wide spread use including the Vr similarity metric and HEAT map analyses for comprehensive characterizations of macromolecular conformational states in solution. The technology and tools Greg developed and implemented at Berkeley lab were instrumental in the early development of Nanotein’s core technology.
A former benchtop PhD biochemist, Patrick acts as Nanotein’s CBO.
Prior to Nanotein, Patrick worked as a mergers & acquisitions and strategy consultant with EY-Parthenon’s biopharma practice. He has also worked in a variety of biotechnology startups, as well as established pharmaceuticals organizations, in roles spanning corporate and portfolio strategy, financial analysis, business development and alliance management.
Patrick earned a PhD in Ocular Biochemistry from UC Berkeley, a Master’s in Management from Harvard University and a Master’s in Molecular Medicine & Biochemistry from USC’s Keck School of Medicine.